Skip to NavigationSkip to content


MSD aims to get the jump on BMS treating bladder cancer

Bristol-Myers Squibb’s Opdivo was only just approved for second-line treatment of bladder cancer, but MSD has attempted to have its own drug, Keytruda, leapfrog them with by having it accepted for priority review in both first and second-line treatments.

FDA clears Opdivo to treat most common form of bladder cancer

Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. The drug will be administered through intravenous injection for 60 minutes every two weeks.

The treatment will be offered to patients who have experienced disease progression during or following platinum-coated chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

BMS receives $625 million patent settlement boost from Merck

Bristol-Myers Squibb were in desperate need of releasing good news after the brief announcement that it would no longer be pursuing an accelerated regulatory pathway for Opdivo with Yervoy, and it revealed some with the news that it had reached a patent infringement settlement with MSD (known as Merck in North America).

MSD and Lilly announce immuno-oncology collaboration

MSD, known as Merck in North America, and Eli Lilly have announced the expansion of their existing immuno-oncology collaboration. The expansion will see MSD’s Keytruda tested alongside Lilly’s Lartruvo (olaratumab) to treat patients with previously treated advanced or metastatic soft tissue sarcoma.

MSD looks to jump the gun with combination immunotherapy application

MSD, known as Merck in North America, has launched a bold move by filing Keytruda, and being accepted, for Priority Review as combination treatment alongside chemotherapy. The move has taken the industry by surprise, as MSD had not been expected to apply so quickly and, if approved, would have a head start on competitors also working on their own combination therapies.

NICE approves MSD’s Keytruda for new cancer indication

The National Institute of Health and Care Excellence (NICE) has announced its recommendation of MSD’s immunotherapy drug Keytruda (pembrolizumab) for the treatment of patients with advanced non-small cell lung cancer who have undergone at least one chemotherapy.

MSD’s Keytruda given first FDA approval for first line treatment

MSD, known as Merck in the US, has scored a big success in treating non-small cell lung cancer (NSCLC), with the FDA approving Keytruda for first-line treatment for the first time. This means that Keytruda will be the first treatment for patients with metastatic NSCLC with high-levels of the protein, PD-L1, that is known for suppressing the immune system.

MSD’s Keytruda early success ends trial early

MSD, known as Merck in the US, ended their Phase III trial of Keytruda for treatment of advanced urothelial cancer early having met its primary endpoint, which was to improve overall survival of patients. Keytruda was found to be superior to chemotherapy and the independent Data Monitoring Committee recommended that the trial be stopped early, as a result.

Failure for BMS' Opdivo in lung cancer trial

Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary endpoint in a new trial investigating the drug’s efficacy in significantly prolonging progression-free survival (PFS) versus chemotherapy.

MSD’s Keytruda twice as successful against standard therapy for lung cancer

MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient study. The results displayed that 55% percent of patients saw their tumours reduce in size using a treatment regimen of Keytruda and two chemotherapy drugs. This compares to 29% who used chemotherapy drugs alone. The trial also revealed that those treated with Keytruda also had a longer period before the disease started growing again and had a lower risk of death.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches